Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway

Multidrug resistance (MDR) is one of the major obstacles to the efficiency of cancer chemotherapy, which often results from the overexpression of drug efflux transporters such as P-glycoprotein (P-gp). In the present study, we determined the effect of dasatinib which was approved for imatinib resist...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Cancer Biol Ther
Κύριοι συγγραφείς: Chen, Ting, Wang, Changyuan, Liu, Qi, Meng, Qiang, Sun, Huijun, Huo, Xiaokui, Sun, Pengyuan, Peng, Jinyong, Liu, Zhihao, Yang, Xiaobo, Liu, Kexin
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Taylor & Francis 2014
Θέματα:
Research Papers
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4622436/
https://ncbi.nlm.nih.gov/pubmed/25482933
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/15384047.2014.987062
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια